Swedish Orphan Biovitrum AB (SE:SOBI)
:SOBI
Want to see SE:SOBI full AI Analyst Report?
Top Page
Swedish Orphan Biovitrum AB
(SOBI)
Select Model
Select Model
Rating:60Neutral
Price Target:
kr424.00
▲(9.11% Upside)
Action:Reiterated
Date:04/29/26
The score is driven primarily by decent financial fundamentals (strong revenue and cash generation but notably weaker net profitability/returns) and a technically supported uptrend. These positives are materially capped by very expensive valuation (high P/E) and the lack of dividend support.
Positive Factors
Specialty rare-disease focus
Sobi’s focus on high‑unmet‑need rare diseases creates durable demand, pricing power and sticky customer relationships. A specialty portfolio plus lifecycle management and in‑/out‑licensing supports steady product revenue and long product lifecycles versus acute therapies.
Negative Factors
Deteriorated net profitability and returns
A marked fall in net profit margin and TTM ROE signals weakening earnings quality and reduced capital returns. If sustained, this lowers internal funding for growth initiatives, increases dependence on partners or external financing, and compresses long‑term investor returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialty rare-disease focus
Sobi’s focus on high‑unmet‑need rare diseases creates durable demand, pricing power and sticky customer relationships. A specialty portfolio plus lifecycle management and in‑/out‑licensing supports steady product revenue and long product lifecycles versus acute therapies.
Read all positive factors
Swedish Orphan Biovitrum AB (SOBI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr152.23B
Dividend YieldN/A
Average Volume (3M)396.16K
Price to Earnings (P/E)25.7
Beta (1Y)1.07
Revenue Growth10.36%
EPS Growth-76.98%
CountrySE
Employees1,895
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.65
Shares Outstanding357,412,840
10 Day Avg. Volume356,894
30 Day Avg. Volume396,160
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)3.04
Price to Sales (P/S)4.06
P/FCF Ratio13.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr471.25Price Target Upside21.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)18.11
Revenue Forecast (FY)kr31.88B
Swedish Orphan Biovitrum AB Business Overview & Revenue Model
Company Description
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America...
How the Company Makes Money
Sobi primarily makes money by selling prescription specialty/rare-disease medicines through its own commercial organizations and via partners in certain geographies. Revenue is largely generated from (1) net product sales of medicines that Sobi ma...
Swedish Orphan Biovitrum AB Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
69
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.95B | 28.24B | 26.03B | 22.12B | 18.79B | 15.53B |
| Gross Profit | 12.79B | 12.32B | 20.24B | 17.13B | 14.01B | 12.04B |
| EBITDA | 11.32B | 10.96B | 9.30B | 7.23B | 6.05B | 5.71B |
| Net Income | 921.00M | 478.00M | 3.88B | 2.41B | 2.64B | 2.68B |
Balance Sheet | ||||||
| Total Assets | 81.26B | 67.43B | 75.44B | 74.03B | 52.50B | 48.66B |
| Cash, Cash Equivalents and Short-Term Investments | 940.00M | 1.04B | 1.14B | 904.00M | 1.36B | 1.04B |
| Total Debt | 19.06B | 11.75B | 16.73B | 20.48B | 9.10B | 10.91B |
| Total Liabilities | 40.87B | 29.71B | 35.15B | 40.16B | 25.97B | 25.46B |
| Stockholders Equity | 40.38B | 37.72B | 40.29B | 33.87B | 26.52B | 23.20B |
Cash Flow | ||||||
| Free Cash Flow | 6.71B | 8.52B | 4.38B | -473.00M | 3.19B | 5.10B |
| Operating Cash Flow | 7.39B | 8.56B | 7.39B | 4.47B | 4.67B | 5.47B |
| Investing Cash Flow | -12.95B | -4.29B | -3.09B | -21.90B | -1.48B | -367.00M |
| Financing Cash Flow | 5.47B | -4.32B | -4.00B | 17.01B | -2.99B | -4.47B |
Swedish Orphan Biovitrum AB Technical Analysis
Positive
388.60
Price Trends
406.61
Positive
386.09
Positive
345.74
Positive
Market Momentum
9.43
Positive
63.51
Neutral
57.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SOBI, the sentiment is Positive. The current price of 388.6 is below the 20-day moving average (MA) of 429.35, below the 50-day MA of 406.61, and above the 200-day MA of 345.74, indicating a bullish trend. The MACD of 9.43 indicates Positive momentum. The RSI at 63.51 is Neutral, neither overbought nor oversold. The STOCH value of 57.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SOBI.
Swedish Orphan Biovitrum AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | kr152.23B | 25.72 | 1.26% | ― | 10.36% | -76.98% | |
53 Neutral | kr695.64M | -1.43 | ― | ― | -58.93% | -16.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr689.64M | -11.63 | -48.65% | ― | 79.13% | 55.77% | |
43 Neutral | kr193.09M | -3.17 | -530.21% | ― | 742.87% | 40.47% | |
43 Neutral | kr33.34M | -0.51 | ― | ― | -86.56% | 8.75% | |
42 Neutral | kr160.31M | -2.22 | -90.66% | ― | ― | -32.29% |
* Healthcare Sector Average
SE:SOBI
Swedish Orphan Biovitrum AB
447.20
151.80
51.39%
SE:ORX
Orexo AB
19.82
4.20
26.89%
SE:ALZCUR
AlzeCure Pharma AB
1.39
-1.16
-45.54%
SE:KLAR
Klaria Pharma Holding AB
0.79
0.04
5.88%
SE:NANEXA
Nanexa AB
3.63
1.51
71.23%
SE:ERMA
Enorama Pharma AB
0.41
-2.08
-83.69%
Swedish Orphan Biovitrum AB Corporate Events
Sobi posts strong Q1 2026 as launches and pipeline deals power growth
Apr 28, 2026
Sobi reported a strong start to 2026, with first-quarter revenue up 24% at constant exchange rates to SEK 7.18 billion and an adjusted EBITA margin of 38%, driven by robust growth in its strategic portfolio and flagship haematology and immunology ...
Sobi Calls 2026 AGM With In-Person and Postal Voting Options
Mar 27, 2026
Swedish Orphan Biovitrum AB has convened its Annual General Meeting for 6 May 2026 in Stockholm, offering shareholders the choice of attending in person or voting by post. Shareholders must be registered with Euroclear Sweden by 27 April 2026 and ...
Sobi Sets Ambitious 2030 Target to Double Revenue on Wave of New Rare-Disease Launches
Feb 18, 2026
Sobi used its 2026 Capital Markets Day to outline an ambitious plan to double revenue to SEK 55 billion by 2030, targeting an adjusted EBITA margin in the upper 30s while keeping RD spending at 11–14% of sales. Management said growth will be...
Sobi Posts Strong 2025 Growth and Expands Rare Disease Portfolio With Strategic Deals and Launches
Feb 5, 2026
Sobi closed 2025 with strong operational momentum, reporting fourth-quarter revenue growth of 16% at constant exchange rates and an adjusted EBITA margin of 41%, driven mainly by a 25% haematology increase and robust demand for Altuvoct and Doptel...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.